{
    "organizations": [],
    "uuid": "73987ac0efc03c2b57573ff0b9a61812bae42bae",
    "author": "",
    "url": "https://www.reuters.com/article/brief-parateks-new-drug-applications-for/brief-parateks-new-drug-applications-for-oral-and-intravenous-omadacycline-accepted-for-priority-review-by-fda-idUSASC09UY2",
    "ord_in_thread": 0,
    "title": "BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4, 2018 / 8:16 PM / in 6 minutes BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA Reuters Staff 1 Min Read \nApril 4 (Reuters) - Paratek Pharmaceuticals Inc: \n* PARATEKâ€™S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA * PDUFA ACTION DATE IN OCTOBER 2018 \n* IN NDA ACCEPTANCE LETTER, FDA STATED THAT NO FILING OR POTENTIAL REVIEW ISSUES WERE IDENTIFIED AT THE TIME Source text for Eikon: Further company coverage:",
    "published": "2018-04-04T23:14:00.000+03:00",
    "crawled": "2018-04-04T23:30:41.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "minute",
        "new",
        "drug",
        "application",
        "oral",
        "intravenous",
        "omadacycline",
        "accepted",
        "priority",
        "review",
        "fda",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "paratek",
        "pharmaceutical",
        "inc",
        "paratek",
        "new",
        "drug",
        "application",
        "oral",
        "intravenous",
        "omadacycline",
        "accepted",
        "priority",
        "review",
        "fda",
        "pdufa",
        "action",
        "date",
        "october",
        "nda",
        "acceptance",
        "letter",
        "fda",
        "stated",
        "filing",
        "potential",
        "review",
        "issue",
        "identified",
        "time",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}